Docoh
Loading...

30 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
22 Apr 21
Definitive proxy
2:00pm
requirements summarized under “Stockholder Proposals” below. Leadership Structure and Risk Oversight Our Board of Directors is currently chaired by David … years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory reporting, and fiscal
10-K/A
2020 FY
PCSA Processa Pharmaceuticals Inc
7 Apr 21
Annual report (amended)
4:23pm
. Stanker has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards, regulatory … reporting, and fiscal management and strategy. He has served in a financial leadership role as an audit partner at Grant Thornton from February 2000 until
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
. Stanker has served as our Chief Financial Officer since September 5, 2018. Mr. Stanker has over 30 years of financial and executive leadershipleadership role as an audit partner at Grant Thornton from February 2000 until his retirement in August 2016. His responsibilities included managing
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
for defibrotide. More recently, Mr. Floyd co-founded Elion Oncology which licensed PCS6422 to Processa. “Adding Mike to our leadership team will enable me … is a proven life science entrepreneur with a demonstrated track record of successfully delivering results. He has the leadership capabilities we are looking
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
, 2018. Mr. Stanker has over 30 years of financial and executive leadership experience in the areas of accounting principles and audit standards … , regulatory reporting, and fiscal management and strategy. He has served in a financial leadership role as an audit partner at Grant Thornton from February
S-1/A
xvdqmev u3
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
ik322mjstatuz631cs58
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-10.4
2useflon71b3ayi
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
i616zfegrao
17 Jul 20
IPO registration (amended)
5:25pm
10-K
8tg8ajh4dg
5 Mar 20
Annual report
7:00pm
8-K
EX-99.1
ew2pzd8smwv72xs
5 Mar 20
Processa Pharmaceuticals Announces Formation of Its Medical and Scientific Advisory Board
9:30am
8-K
EX-99.1
99rbrun1prr
13 Feb 20
Processa Pharmaceuticals Appoints
9:30am
S-1
kbc5qgk
13 Dec 19
IPO registration
5:32pm
DEF 14A
suxmw36l0781zib4qq0
26 Apr 19
Definitive proxy
5:02pm
10-K/A
g6p5y0d61ug9tc0ds7q
5 Apr 19
Annual report (amended)
9:40pm
10-K
85kqz2ma6nn li9skl
28 Mar 19
Annual report
5:25pm
424B3
rdwosijon
9 Nov 18
Prospectus supplement
5:04pm
S-1/A
t1idg0axc5w08hnuhhu6
30 Oct 18
IPO registration (amended)
4:19pm
S-1/A
254xyi4
9 Oct 18
IPO registration (amended)
5:32pm
S-1/A
vde8yoath pj
13 Sep 18
IPO registration (amended)
8:00pm